NEW YORK, June 03, 2024 Royalty Pharma plc announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following : $500 million of 5.150% Notes.
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented.
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy
Innovent looks to Chinese regulators after ph. 3 psoriasis win fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.